ArticleClinical and translational medicine2026
Ubc9-mediated SUMOylation of Ninj1 alleviates inflammatory responses in hepatic ischaemia/reperfusion injury.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHepatic ischaemia/reperfusion (I/R) injury poses a common clinical dilemma encountered during liver transplantation (LT), characterised by substantial cellular death and inflammation reactions. Ubc9, the sole E2 conjugating enzyme of SUMOylation, has long been recognised to regulate diverse biological and pathological processes. However, its impact on I/R-induced liver damage is yet to be elucidated.
methodsThe expression levels of UBC9 in patients undergoing LT were analysed. Hepatocyte-specific Ubc9-deficient or transgenic mice were utilised in an in vivo model of hepatic I/R, alongside in vitro experiments that employed hypoxia/reoxygenation stimulation. The investigation focused on Ubc9's role in liver damage due to I/R and the underlying mechanisms through a range of phenotypic analyses and biological techniques.
resultsHerein, we found that hepatic tissues from patients with LT are featured by a significant downregulation of UBC9 expression. Studies in 68 donor hepatic biopsies further demonstrated a negative correlation between UBC9 expression and liver injury in patients with LT. Similarly, murine liver I/R was coupled with an obvious decrease in Ubc9 expression. Hepatocyte deficient in Ubc9 exacerbated liver injury in liver I/R, while Ubc9-overexpression showed the opposite phenotype. Mechanistically, Ubc9-mediated SUMOylation of Ninj1 at lysine K103 inhibited its membrane localisation and damage-associated molecular patterns (DAMPs) release in hepatocytes, subsequently inhibited nuclear factor-kappa B (NF-κB) signalling in macrophages and curtailing inflammatory cytokines production.
conclusionsThese findings further suggest that Ubc9-mediated SUMOylation of Ninj1 at lysine K103 may represent a potential therapeutic strategy for safeguarding the liver against I/R injury in clinical settings. KEY POINTS: Ubc9 expression is downregulated in hepatocytes during hepatic ischaemia/reperfusion (I/R) injury. Higher UBC9 expression is associated with improved post-liver transplantation (LT) liver function. Ubc9 ameliorates liver damage and inflammation responses in hepatic I/R injury. Ubc9-mediated Ninj1 SUMOylation at K103 is essential for regulating the subcellular distribution of Ninj1. Ubc9 inhibits the release of hepatocyte-derived damage-associated molecular patterns (DAMPs) in a Ninj1 K103 SUMOylation-dependent manner.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.